Better COVID Stock: Pfizer vs. Moderna
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) both have generated billions of dollars in revenue, thanks to their coronavirus vaccines. They both dominate the U.S. market.
Pfizer has fully vaccinated more than 127 million Americans, while Moderna has vaccinated nearly 77 million. But their stock prices haven't followed the same path. Since the start of the pandemic, Moderna's shares have soared more than 600%, while Pfizer's stock has gained about 45%.
When I ask, "which is the better COVID stock?" the answer might seem obvious. But actually, it isn't. There are reasons to like both of these vaccine giants. Let's take a closer look at each player and see which one really is the best stock to buy now.
Source Fool.com
